As reported in the European Medical Journal, new research suggests that cherry angiomas occur more frequently and at an earlier age in people with neurofibromatosis
In a recent press release, BioCryst Pharmaceuticals has shared that it received approval from Japan’s Ministry of Health, Labour and Welfare for the use of
As reported on Inside Precision Medicine, a new, non-invasive test may help doctors detect oral cancer quickly and reduce the need for painful scalpel biopsies.
Have you ever looked in the mirror and wondered, “Who am I now? Why did this diagnosis happen to me? When will this be over?
As reported on Pharma Phorum, Roivant Sciences and its subsidiary Priovant Therapeutics have received U.S. Food and Drug Administration (FDA) approval for Lisraya (brepocitinib), marking
As reported on Business Wire, AstraZeneca has finalized its previously announced licensing agreement with Dizal Pharmaceutical, gaining exclusive worldwide rights to develop and market ZEGFROVY
Treating acute ischemic strokes involves a precarious clinical balance: physicians must dissolve arterial clots to save brain tissue without triggering catastrophic intracranial hemorrhaging. To address
Editor’s Note: Patient Worthy is honored to share the following article, originally published by our friends at CURE SYNGAP1. To see the article in its
A Sustainable Biologic Solution Gains Major Insurance Coverage and Proves Superior to Synthetic Alternatives in Real-World Clinical Data In the world of advanced wound care
As reported on PharmaBiz, a new study published in Cell Stem Cell highlights a promising approach to cancer immunotherapy that combines stem cell technology with
As reported on BioPharmaDive, Moderna captured attention this week with two major developments: a multibillion-dollar financing initiative aimed at expanding its oncology portfolio and regulatory
As reported on PR NewsWire, Orsini has been named a specialty pharmacy partner for Priovant’s LISRAYA™ (brepocitinib), a once-daily oral treatment recently approved by the
As reported on Healio, the phase 3 CARDIO-TTRansform study, the largest clinical trial conducted to date in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), found
For a long time, I knew something was wrong. And then, when whatever had been building inside my body finally came to the surface, it
RASONQUE Represents a Watershed Moment for a Disease That Has Resisted Treatment Since RAS Was Discovered as a Cancer-Causing Gene Pancreatic cancer is among the
A Rare Disease Gets Its First FDA-Approved Medicine—And It Works Differently Than Anything Available Before Imagine your immune system getting the signals completely wrong. Instead
Twenty-plus pills a day. Two biologic injections a month, two more every week. That’s my baseline just to function like a “normie” human and keep
Editor’s Note: Patient Worthy is honored to share this article, originally written by Danviel Villarte . Danviel is part of the Outreach Team at Receptive,
❤️ This Blood Cancer Awareness Month, let's raise our voices for those affected by leukemia, lymphoma, multiple myeloma, and other blood cancers.
Awareness leads to understanding. Understanding leads to action. And action leads to hope.
Together, we can make an impact. 🩸
#BloodCancerAwareness #PatientWorthy #InspireHope #PatientCommunity #bloodcancermonth
September is Childhood Cancer Awareness Month.
This month, we honor the children facing cancer, remember those we’ve lost, and stand alongside the families, caregivers, survivors, and advocates whose lives have been forever changed by a childhood cancer diagnosis.
Every child deserves a future filled with more than treatments and hospital visits. This month and always, we raise awareness, share stories, and support the continued push for better treatments and brighter tomorrows.
#ChildhoodCancerAwarenessMonth #ChildhoodCancerAwareness #GoGold #PediatricCancer #CancerAwareness #PatientWorthy
When swelling keeps coming back, finding the reason matters.
Hereditary angioedema can be difficult to recognize because its symptoms can resemble other conditions, and attacks may look different from one person to another. That’s why understanding the signs and knowing when HAE testing may be appropriate can make an important difference.
Diagnosis involves specific blood tests that look at C4 and C1 esterase inhibitor levels and function, helping healthcare professionals determine whether HAE may be present and which type may be involved.
If you or your loved one would like to share about your HAE story, click the link below!
ow.ly/oTqo50ZHtwX
#HereditaryAngioedema #HAE #HAEAwareness #PatientWorthy
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
